Key result
Guided and unguided DAPT de-escalation from potent P2Y12 inhibitors to clopidogrel may prevent bleeding complications without increasing ischemic risk in ACS patients.
Why the study?
Does DAPT de-escalation prevent bleeding complications without increasing ischemic risk in ACS patients undergoing PCI?
Does DAPT de-escalation prevent bleeding complications without increasing ischemic risk in ACS patients undergoing PCI?
Guided DAPT de-escalation from potent P2Y12 inhibitors to clopidogrel may be a safe alternative to reduce bleeding in selected ACS patients after PCI, while unguided de-escalation requires further study.
No takes yet. Share an insight, caveat, or question.
May support DAPT de-escalation in ACS to curb bleeding; leaves open confirmation by large-scale RCTs.
Kupka et al. (2018) conducted a review in Acute Coronary Syndrome. DAPT de-escalation (switch from ticagrelor or prasugrel to clopidogrel) vs. Standard DAPT (continuation of potent P2Y12 inhibitors) was evaluated. Guided and unguided DAPT de-escalation from potent P2Y12 inhibitors to clopidogrel may prevent bleeding complications without increasing ischemic risk in ACS patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: